RET and neoplasm: On the other hand, if specific driver mutations are identified (eg, NTRK, ALK, RET, BRAF), new mutation-specific kinase inhibitor should be considered which have been FDA-approved, specifically for TCs or for any tumor type harboring the same molecular target (7, 23, 81, 82).